---
title: "12 Health Care Stocks Moving In Monday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302287808.md"
description: "During Monday's pre-market session, several healthcare stocks experienced significant volatility. Disc Medicine (IRON) surged 50.4% to $85.51, while DataMEDS AI (MEDS) rose 19.77%. Other gainers included Virax Biolabs (VRAX), Alaunos Therapeutics (TCRT), Akari Therapeutics (AKTX), and Rapport Therapeutics (RAPP). Conversely, EyePoint Pharmaceuticals (EYPT) plummeted 80.0% to $0.60. Additional decliners were CDT Equity (CDT), Actuate Therapeutics (ACTU), Sera Prognostics (SERA), Matinas BioPharma (MTNB), and Estrella Immunopharma (ESLA)."
datetime: "2026-10-19T12:05:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302287808.md)
  - [en](https://longbridge.com/en/news/302287808.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302287808.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Monday's Pre-Market Session

### Gainers

-   **Disc Medicine** (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion.
-   **DataMEDS AI** (NASDAQ:MEDS) shares moved upwards by 19.77% to $3.15. The market value of their outstanding shares is at $9.1 million.
-   **Virax Biolabs Group** (NASDAQ:VRAX) stock moved upwards by 17.24% to $1.7. The company's market cap stands at $1.2 million.
-   **Alaunos Therapeutics** (NASDAQ:TCRT) stock rose 17.11% to $3.08. The company's market cap stands at $5.5 million.
-   **Akari Therapeutics** (NASDAQ:AKTX) stock rose 13.01% to $9.24. The market value of their outstanding shares is at $20.2 million.
-   **Rapport Therapeutics** (NASDAQ:RAPP) shares rose 12.44% to $31.0. The company's market cap stands at $1.4 billion.

### Losers

-   **EyePoint** (NASDAQ:EYPT) shares decreased by 80.0% to $0.6 during Monday's pre-market session. The company's market cap stands at $270.7 million.
-   **CDT Equity** (NASDAQ:CDT) stock declined by 12.81% to $0.2.
-   **Actuate Therapeutics** (NASDAQ:ACTU) shares decreased by 12.32% to $0.53. The company's market cap stands at $12.0 million.
-   **Sera Prognostics** (NASDAQ:SERA) stock fell 10.2% to $1.85. The company's market cap stands at $80.0 million.
-   **Matinas BioPharma Hldgs** (AMEX:MTNB) stock decreased by 9.29% to $2.15. The market value of their outstanding shares is at $35.5 million.
-   **Estrella Immunopharma** (NASDAQ:ESLA) stock decreased by 8.45% to $0.39. The market value of their outstanding shares is at $23.2 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ACTU.US](https://longbridge.com/en/quote/ACTU.US.md)
- [AKTX.US](https://longbridge.com/en/quote/AKTX.US.md)
- [CDT.US](https://longbridge.com/en/quote/CDT.US.md)
- [ESLA.US](https://longbridge.com/en/quote/ESLA.US.md)
- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)
- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)
- [MEDS.US](https://longbridge.com/en/quote/MEDS.US.md)
- [MTNB.US](https://longbridge.com/en/quote/MTNB.US.md)
- [RAPP.US](https://longbridge.com/en/quote/RAPP.US.md)
- [SERA.US](https://longbridge.com/en/quote/SERA.US.md)
- [TCRT.US](https://longbridge.com/en/quote/TCRT.US.md)
- [VRAX.US](https://longbridge.com/en/quote/VRAX.US.md)

## Related News & Research

- [BUZZ-Disc Medicine down after $450 mln equity raise following rare disease drug trial success](https://longbridge.com/en/news/302555358.md)
- [BUZZ-Disc Medicine dips after launching $350 stock offering](https://longbridge.com/en/news/302325327.md)
- [Inside the $1 billion blockbuster opportunity sending Rapport Therapeutics stock higher](https://longbridge.com/en/news/302461639.md)
- [BUZZ-Rapport surges as bipolar mania drug succeeds mid-stage trial](https://longbridge.com/en/news/302403451.md)
- [Rapport Therapeutics CFO Troy A. Ignelzi Reports Purchase of $143,550 in Common Shares](https://longbridge.com/en/news/302614876.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**